Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHFR | P00374 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | XBP1 | P17861 | 1/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.41 |
| ▸ | AGPAT2 | O15120 | 2/20 | 0.40 |
| ▸ | HTR2B | P41595 | 1/20 | 0.38 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.38 |
| ▸ | PDE2A | O00408 | 1/20 | 0.37 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6049509 | 0.84 | HTR2B (0.56) | DHFRAGPAT2HTR2BPDE4DPDE2A | |
| SCHEMBL6049515 | 0.84 | DHFR (0.49) | DHFRMAPTHTR2BPDE4DSMN1; SMN2 | |
| SCHEMBL6049512 | 0.82 | DHFR (0.47) | DHFRAGPAT2HTR2BPDE4DPDE2A | |
| SCHEMBL6049638 | 0.82 | DHFR (0.47) | DHFRHTR2BPDE4DSMN1; SMN2 | |
| SCHEMBL6049667 | 0.79 | DHFR (0.44) | DHFRHTR2BPDE4DSMN1; SMN2 | |
| SCHEMBL6049621 | 0.79 | DHFR (0.49) | DHFR | |
| SCHEMBL6049516 | 0.78 | DHFR (0.43) | DHFRMAPTHIF1AHTR2BPDE4D | |
| SCHEMBL6049555 | 0.78 | DHFR (0.64) | DHFRMAPTHIF1A | |
| SCHEMBL6049570 | 0.76 | DHFR (0.50) | DHFRHTR2BPDE4DSMN1; SMN2 | |
| SCHEMBL6049466 | 0.76 | DHFR (0.46) | DHFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1681058-A2 | Pharmacologically active cns compounds | THE WELLCOME FOUNDATION LIMITED (GB) | 2006-07-19 | — | — | EP | disclosed |
| EP-1325916-A1 | Piperazinyl-substituted phenyl pyrimidine derivatives useful in the treatment or prevention of disorders of the central nervous system | THE WELLCOME FOUNDATION LIMITED (GB) | 2003-07-09 | — | — | EP | disclosed |
| CN-1066720-C | Process for preparing compounds having pharmacological activity on the central nervous system | WELLCOME FOUND (GB) | 2001-06-06 | — | — | CN | disclosed |
| CN-1066719-C | Process for preparing compounds having pharmacological activity on the central nervous system | WELLCOME FOUND (GB) | 2001-06-06 | — | — | CN | disclosed |
| US-5712276-A | TREATING NERVOUS SYSTEM DISORDERS | GLAXO WELLCOME INC. (US) | 1998-01-27 | — | — | US | disclosed |
| US-5684005-A | PHENYLPYRIMIDINE COMPOUNDS AS INHIBITORS OF EXCITATORY AMINO ACID GLUTAMATE | GLAXO WELLCOME INC. (US) | 1997-11-04 | — | — | US | disclosed |
| US-5635507-A | PIPERAZINYL PHENYLPYRIMIDINE COMPOUND TREATING BRAIN DISORDER | GLAXO WELLCOME INC. (US) | 1997-06-03 | — | — | US | disclosed |
| US-5597828-A | TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS SUCH AS CEREBRAL ISCHEMIC DAMAGE AND EPILEPSY | GLAXO WELLCOME INC. (US) | 1997-01-28 | — | — | US | disclosed |
| US-5597827-A | CENTRAL NERVOUS SYSTEM DISORDERS AND ANTIISCHEMIC AGENTS | GLAXO WELLCOME INC. | 1997-01-28 | — | — | US | disclosed |
| US-5591746-A | GLUTAMATE INHIBITORS; CENTRAL NERVOUS SYSTEM DISORDERS | GLAXO WELLCOME INC. | 1997-01-07 | — | — | US | disclosed |
| US-5587380-A | ANTIISCHEMIC AGENTS | GLAXO WELLCOME INC. (US) | 1996-12-24 | — | — | US | disclosed |
| EP-0727214-A2 | Substituted phenylpyrimidine derivatives, useful in the treatment or prevention of CNS disorders | THE WELLCOME FOUNDATION LIMITED (GB) | 1996-08-21 | — | — | EP | disclosed |
| EP-0727213-A2 | Substituted phenylpyrimidine derivatives, useful in the treatment or prevention of CNS disorders | THE WELLCOME FOUNDATION LIMITED (GB) | 1996-08-21 | — | — | EP | disclosed |
| EP-0727212-A2 | Substituted phenylpyrimidine derivatives, useful in the treatment of prevention of CNS disorders | THE WELLCOME FOUNDATION LIMITED (GB) | 1996-08-21 | — | — | EP | disclosed |
| EP-0715851-A2 | Substituted phenylpyrimidine derivatives, useful in the treatment of prevention of CNS disorders | THE WELLCOME FOUNDATION LIMITED (GB) | 1996-06-12 | — | — | EP | disclosed |
| EP-0713703-A2 | Substituted phenylpyrimidine derivatives, useful in the treatment or prevention of CNS disorders | THE WELLCOME FOUNDATION LIMITED (GB) | 1996-05-29 | — | — | EP | disclosed |
| CN-1117046-A | Method for preparing pharmaceutically active CNS compounds | WELLCOME FOUND (GB) | 1996-02-21 | — | — | CN | disclosed |
| CN-1115756-A | Method for preparing pharmaceutically active CNS compounds | WELLCOME FOUND (GB) | 1996-01-31 | — | — | CN | disclosed |
| US-5136080-A | Intermediates for glutamate inhibitors | BURROUGHS WELLCOME CO. (US) | 1992-08-04 | — | — | US | disclosed |
| EP-0372934-A2 | Pharmacologically active CNS compounds | THE WELLCOME FOUNDATION LIMITED (GB) | 1990-06-13 | — | — | EP | disclosed |